SubHero Banner

Renflexis® (infliximab-abda) – Expanded indication

June 26, 2019 - FDA approved Samsung Bioepis’ Renflexis (infliximab-abda), for reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active ulcerative colitis (UC) who have had an inadequate response to conventional therapy.

Download PDF